nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—hematologic cancer—muscle cancer	0.129	0.237	CtDrD
Methotrexate—PGD—Dacarbazine—muscle cancer	0.0999	0.291	CbGbCtD
Methotrexate—urinary bladder cancer—muscle cancer	0.0992	0.182	CtDrD
Methotrexate—bone cancer—muscle cancer	0.0951	0.174	CtDrD
Methotrexate—testicular cancer—muscle cancer	0.0788	0.144	CtDrD
Methotrexate—germ cell cancer—muscle cancer	0.0755	0.138	CtDrD
Methotrexate—lung cancer—muscle cancer	0.0678	0.124	CtDrD
Methotrexate—ABCC10—Vincristine—muscle cancer	0.0306	0.0893	CbGbCtD
Methotrexate—ABCC10—Etoposide—muscle cancer	0.0281	0.0818	CbGbCtD
Methotrexate—ABCC3—Vincristine—muscle cancer	0.0193	0.0562	CbGbCtD
Methotrexate—ABCC1—Dactinomycin—muscle cancer	0.0192	0.056	CbGbCtD
Methotrexate—ABCC10—Doxorubicin—muscle cancer	0.0191	0.0558	CbGbCtD
Methotrexate—ABCC3—Etoposide—muscle cancer	0.0177	0.0515	CbGbCtD
Methotrexate—ABCG2—Dactinomycin—muscle cancer	0.0129	0.0375	CbGbCtD
Methotrexate—ABCC3—Doxorubicin—muscle cancer	0.012	0.0351	CbGbCtD
Methotrexate—ABCC1—Vincristine—muscle cancer	0.0118	0.0345	CbGbCtD
Methotrexate—ABCC1—Etoposide—muscle cancer	0.0108	0.0316	CbGbCtD
Methotrexate—ABCC2—Vincristine—muscle cancer	0.00875	0.0255	CbGbCtD
Methotrexate—ABCC2—Etoposide—muscle cancer	0.00802	0.0234	CbGbCtD
Methotrexate—ABCG2—Vincristine—muscle cancer	0.00791	0.0231	CbGbCtD
Methotrexate—ABCC1—Doxorubicin—muscle cancer	0.00739	0.0216	CbGbCtD
Methotrexate—ABCG2—Etoposide—muscle cancer	0.00725	0.0211	CbGbCtD
Methotrexate—ABCC2—Doxorubicin—muscle cancer	0.00547	0.016	CbGbCtD
Methotrexate—ABCG2—Doxorubicin—muscle cancer	0.00495	0.0144	CbGbCtD
Methotrexate—ATIC—pes—muscle cancer	0.00478	0.119	CbGeAlD
Methotrexate—ABCB1—Dactinomycin—muscle cancer	0.00463	0.0135	CbGbCtD
Methotrexate—ABCB1—Vincristine—muscle cancer	0.00285	0.00832	CbGbCtD
Methotrexate—AOX1—Effects of Nitric Oxide—MB—muscle cancer	0.00269	0.251	CbGpPWpGaD
Methotrexate—ABCB1—Etoposide—muscle cancer	0.00262	0.00762	CbGbCtD
Methotrexate—ATIC—hindlimb—muscle cancer	0.00217	0.0543	CbGeAlD
Methotrexate—ATIC—appendage—muscle cancer	0.00187	0.0466	CbGeAlD
Methotrexate—ABCB1—Doxorubicin—muscle cancer	0.00178	0.0052	CbGbCtD
Methotrexate—ABCC11—embryo—muscle cancer	0.00105	0.0262	CbGeAlD
Methotrexate—FOLR1—renal system—muscle cancer	0.00083	0.0207	CbGeAlD
Methotrexate—ATIC—embryo—muscle cancer	0.000619	0.0155	CbGeAlD
Methotrexate—GGH—smooth muscle tissue—muscle cancer	0.000573	0.0143	CbGeAlD
Methotrexate—FOLR1—head—muscle cancer	0.000555	0.0139	CbGeAlD
Methotrexate—GGH—renal system—muscle cancer	0.000551	0.0138	CbGeAlD
Methotrexate—ABCC11—testis—muscle cancer	0.000514	0.0128	CbGeAlD
Methotrexate—SLCO4C1—renal system—muscle cancer	0.000489	0.0122	CbGeAlD
Methotrexate—ATIC—smooth muscle tissue—muscle cancer	0.000487	0.0122	CbGeAlD
Methotrexate—SLC19A1—head—muscle cancer	0.000487	0.0122	CbGeAlD
Methotrexate—SLC19A1—testis—muscle cancer	0.00047	0.0117	CbGeAlD
Methotrexate—ATIC—renal system—muscle cancer	0.000469	0.0117	CbGeAlD
Methotrexate—SLC46A1—tendon—muscle cancer	0.000438	0.0109	CbGeAlD
Methotrexate—FPGS—cardiac atrium—muscle cancer	0.000434	0.0108	CbGeAlD
Methotrexate—GGH—tendon—muscle cancer	0.00043	0.0107	CbGeAlD
Methotrexate—TYMS—Vinorelbine—Vincristine—muscle cancer	0.000423	0.372	CbGdCrCtD
Methotrexate—TYMS—Podofilox—Etoposide—muscle cancer	0.000422	0.372	CbGdCrCtD
Methotrexate—GGH—bone marrow—muscle cancer	0.000417	0.0104	CbGeAlD
Methotrexate—DHFR—embryo—muscle cancer	0.000416	0.0104	CbGeAlD
Methotrexate—GGH—vagina—muscle cancer	0.000399	0.00997	CbGeAlD
Methotrexate—SLC16A1—Pyruvate metabolism and Citric Acid (TCA) cycle—FH—muscle cancer	0.000394	0.0368	CbGpPWpGaD
Methotrexate—SLCO1C1—renal system—muscle cancer	0.00039	0.00974	CbGeAlD
Methotrexate—SLC22A11—renal system—muscle cancer	0.000379	0.00946	CbGeAlD
Methotrexate—FPGS—tendon—muscle cancer	0.000378	0.00945	CbGeAlD
Methotrexate—SLC46A1—head—muscle cancer	0.000375	0.00937	CbGeAlD
Methotrexate—SLCO4C1—bone marrow—muscle cancer	0.00037	0.00923	CbGeAlD
Methotrexate—SLC22A7—renal system—muscle cancer	0.00037	0.00923	CbGeAlD
Methotrexate—GGH—head—muscle cancer	0.000369	0.00921	CbGeAlD
Methotrexate—SLC46A1—testis—muscle cancer	0.000362	0.00905	CbGeAlD
Methotrexate—GGH—testis—muscle cancer	0.000356	0.0089	CbGeAlD
Methotrexate—SLCO4C1—vagina—muscle cancer	0.000354	0.00885	CbGeAlD
Methotrexate—FPGS—vagina—muscle cancer	0.000351	0.00877	CbGeAlD
Methotrexate—SLCO1B3—vagina—muscle cancer	0.000344	0.0086	CbGeAlD
Methotrexate—SLCO3A1—renal system—muscle cancer	0.000343	0.00856	CbGeAlD
Methotrexate—TYMS—smooth muscle tissue—muscle cancer	0.00033	0.00825	CbGeAlD
Methotrexate—DHFR—E2F transcription factor network—TFE3—muscle cancer	0.000329	0.0308	CbGpPWpGaD
Methotrexate—FPGS—head—muscle cancer	0.000324	0.0081	CbGeAlD
Methotrexate—GGH—Fluoropyrimidine Activity—TP53—muscle cancer	0.000317	0.0297	CbGpPWpGaD
Methotrexate—DHFR—renal system—muscle cancer	0.000315	0.00786	CbGeAlD
Methotrexate—PGD—smooth muscle tissue—muscle cancer	0.000314	0.00785	CbGeAlD
Methotrexate—ATIC—head—muscle cancer	0.000314	0.00783	CbGeAlD
Methotrexate—FPGS—testis—muscle cancer	0.000313	0.00782	CbGeAlD
Methotrexate—SLCO3A1—cardiac atrium—muscle cancer	0.000307	0.00767	CbGeAlD
Methotrexate—ATIC—testis—muscle cancer	0.000303	0.00757	CbGeAlD
Methotrexate—PGD—renal system—muscle cancer	0.000303	0.00756	CbGeAlD
Methotrexate—TYMS—Vinblastine—Vincristine—muscle cancer	0.000291	0.256	CbGdCrCtD
Methotrexate—TYMS—E2F transcription factor network—TFE3—muscle cancer	0.000287	0.0269	CbGpPWpGaD
Methotrexate—SLC16A1—renal system—muscle cancer	0.000283	0.00706	CbGeAlD
Methotrexate—DHFR—cardiac atrium—muscle cancer	0.000282	0.00704	CbGeAlD
Methotrexate—SLCO1B1—renal system—muscle cancer	0.000275	0.00686	CbGeAlD
Methotrexate—PGD—cardiac atrium—muscle cancer	0.000271	0.00677	CbGeAlD
Methotrexate—SLCO3A1—tendon—muscle cancer	0.000268	0.00668	CbGeAlD
Methotrexate—AOX1—renal system—muscle cancer	0.000267	0.00666	CbGeAlD
Methotrexate—SLCO1C1—head—muscle cancer	0.000261	0.00651	CbGeAlD
Methotrexate—ABCC3—renal system—muscle cancer	0.000261	0.00651	CbGeAlD
Methotrexate—ABCC10—renal system—muscle cancer	0.00026	0.00648	CbGeAlD
Methotrexate—SLC16A1—cardiac atrium—muscle cancer	0.000253	0.00632	CbGeAlD
Methotrexate—SLCO1C1—testis—muscle cancer	0.000252	0.00629	CbGeAlD
Methotrexate—SLCO3A1—vagina—muscle cancer	0.000248	0.0062	CbGeAlD
Methotrexate—TYMS—tendon—muscle cancer	0.000248	0.0062	CbGeAlD
Methotrexate—DHFR—tendon—muscle cancer	0.000246	0.00614	CbGeAlD
Methotrexate—TYMS—bone marrow—muscle cancer	0.00024	0.006	CbGeAlD
Methotrexate—FOLR1—Folate Metabolism—TP53—muscle cancer	0.00024	0.0225	CbGpPWpGaD
Methotrexate—SLC22A7—testis—muscle cancer	0.000239	0.00596	CbGeAlD
Methotrexate—AOX1—cardiac atrium—muscle cancer	0.000239	0.00596	CbGeAlD
Methotrexate—DHFR—bone marrow—muscle cancer	0.000238	0.00594	CbGeAlD
Methotrexate—PGD—tendon—muscle cancer	0.000236	0.0059	CbGeAlD
Methotrexate—MTHFR—head—muscle cancer	0.000233	0.00582	CbGeAlD
Methotrexate—ABCC10—cardiac atrium—muscle cancer	0.000232	0.0058	CbGeAlD
Methotrexate—TYMS—vagina—muscle cancer	0.00023	0.00575	CbGeAlD
Methotrexate—SLCO3A1—head—muscle cancer	0.000229	0.00573	CbGeAlD
Methotrexate—PGD—bone marrow—muscle cancer	0.000229	0.00572	CbGeAlD
Methotrexate—DHFR—vagina—muscle cancer	0.000228	0.00569	CbGeAlD
Methotrexate—MTHFR—testis—muscle cancer	0.000225	0.00562	CbGeAlD
Methotrexate—SLCO1A2—renal system—muscle cancer	0.000224	0.00559	CbGeAlD
Methotrexate—DHFR—E2F transcription factor network—TP73—muscle cancer	0.000223	0.0208	CbGpPWpGaD
Methotrexate—SLCO3A1—testis—muscle cancer	0.000222	0.00553	CbGeAlD
Methotrexate—SLC16A1—tendon—muscle cancer	0.000221	0.00551	CbGeAlD
Methotrexate—PGD—vagina—muscle cancer	0.000219	0.00548	CbGeAlD
Methotrexate—ABCC4—renal system—muscle cancer	0.000215	0.00538	CbGeAlD
Methotrexate—SLC22A8—renal system—muscle cancer	0.000214	0.00533	CbGeAlD
Methotrexate—TYMS—head—muscle cancer	0.000213	0.00531	CbGeAlD
Methotrexate—DHFR—head—muscle cancer	0.000211	0.00526	CbGeAlD
Methotrexate—ABCC2—renal system—muscle cancer	0.000208	0.0052	CbGeAlD
Methotrexate—AOX1—tendon—muscle cancer	0.000208	0.0052	CbGeAlD
Methotrexate—TYMS—testis—muscle cancer	0.000206	0.00513	CbGeAlD
Methotrexate—DHFR—testis—muscle cancer	0.000203	0.00508	CbGeAlD
Methotrexate—ABCC10—tendon—muscle cancer	0.000203	0.00506	CbGeAlD
Methotrexate—PGD—head—muscle cancer	0.000203	0.00506	CbGeAlD
Methotrexate—ABCC10—bone marrow—muscle cancer	0.000196	0.0049	CbGeAlD
Methotrexate—PGD—testis—muscle cancer	0.000196	0.00489	CbGeAlD
Methotrexate—TYMS—E2F transcription factor network—TP73—muscle cancer	0.000194	0.0182	CbGpPWpGaD
Methotrexate—AOX1—vagina—muscle cancer	0.000193	0.00482	CbGeAlD
Methotrexate—SLC16A1—head—muscle cancer	0.000189	0.00472	CbGeAlD
Methotrexate—ABCC10—vagina—muscle cancer	0.000188	0.00469	CbGeAlD
Methotrexate—SLC16A1—testis—muscle cancer	0.000183	0.00456	CbGeAlD
Methotrexate—ABCC3—head—muscle cancer	0.000175	0.00436	CbGeAlD
Methotrexate—AOX1—testis—muscle cancer	0.000172	0.0043	CbGeAlD
Methotrexate—ABCC3—testis—muscle cancer	0.000169	0.00421	CbGeAlD
Methotrexate—ABCC4—tendon—muscle cancer	0.000168	0.0042	CbGeAlD
Methotrexate—ABCC10—testis—muscle cancer	0.000168	0.00419	CbGeAlD
Methotrexate—ABCC1—cardiac atrium—muscle cancer	0.000164	0.00411	CbGeAlD
Methotrexate—ABCC4—bone marrow—muscle cancer	0.000163	0.00407	CbGeAlD
Methotrexate—ABCC2—tendon—muscle cancer	0.000163	0.00406	CbGeAlD
Methotrexate—SLC16A1—The citric acid (TCA) cycle and respiratory electron transport—FH—muscle cancer	0.000153	0.0143	CbGpPWpGaD
Methotrexate—SLCO1A2—head—muscle cancer	0.00015	0.00374	CbGeAlD
Methotrexate—SLC16A1—Cell surface interactions at the vascular wall—ANGPT2—muscle cancer	0.000145	0.0136	CbGpPWpGaD
Methotrexate—SLCO1A2—testis—muscle cancer	0.000145	0.00361	CbGeAlD
Methotrexate—ABCC4—head—muscle cancer	0.000144	0.0036	CbGeAlD
Methotrexate—ALB—testis—muscle cancer	0.000144	0.00359	CbGeAlD
Methotrexate—ABCC1—tendon—muscle cancer	0.000143	0.00358	CbGeAlD
Methotrexate—SLC22A8—head—muscle cancer	0.000143	0.00357	CbGeAlD
Methotrexate—FPGS—Fluoropyrimidine Activity—TP53—muscle cancer	0.000142	0.0132	CbGpPWpGaD
Methotrexate—ABCC4—testis—muscle cancer	0.000139	0.00347	CbGeAlD
Methotrexate—ABCC2—testis—muscle cancer	0.000135	0.00336	CbGeAlD
Methotrexate—ABCC4—Ectoderm Differentiation—PAX3—muscle cancer	0.000134	0.0126	CbGpPWpGaD
Methotrexate—ABCC1—vagina—muscle cancer	0.000133	0.00332	CbGeAlD
Methotrexate—SLC19A1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	0.000129	0.0121	CbGpPWpGaD
Methotrexate—ABCC3—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000127	0.0119	CbGpPWpGaD
Methotrexate—ABCC1—testis—muscle cancer	0.000119	0.00296	CbGeAlD
Methotrexate—ABCG2—bone marrow—muscle cancer	0.000115	0.00287	CbGeAlD
Methotrexate—ABCG2—vagina—muscle cancer	0.00011	0.00275	CbGeAlD
Methotrexate—FPGS—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	0.00011	0.0103	CbGpPWpGaD
Methotrexate—Bone disorder—Doxorubicin—muscle cancer	0.000107	0.0018	CcSEcCtD
Methotrexate—Skin discolouration—Doxorubicin—muscle cancer	0.000107	0.0018	CcSEcCtD
Methotrexate—Hyperbilirubinaemia—Doxorubicin—muscle cancer	0.000106	0.00179	CcSEcCtD
Methotrexate—Oliguria—Doxorubicin—muscle cancer	0.000105	0.00176	CcSEcCtD
Methotrexate—Glossitis—Doxorubicin—muscle cancer	0.000105	0.00176	CcSEcCtD
Methotrexate—Herpes simplex—Doxorubicin—muscle cancer	0.000105	0.00176	CcSEcCtD
Methotrexate—Pneumonia—Etoposide—muscle cancer	0.000105	0.00176	CcSEcCtD
Methotrexate—Angiopathy—Vincristine—muscle cancer	0.000105	0.00176	CcSEcCtD
Methotrexate—Ill-defined disorder—Dactinomycin—muscle cancer	0.000105	0.00176	CcSEcCtD
Methotrexate—Infestation NOS—Etoposide—muscle cancer	0.000104	0.00175	CcSEcCtD
Methotrexate—Infestation—Etoposide—muscle cancer	0.000104	0.00175	CcSEcCtD
Methotrexate—Hyperuricaemia—Doxorubicin—muscle cancer	0.000104	0.00175	CcSEcCtD
Methotrexate—Mediastinal disorder—Vincristine—muscle cancer	0.000104	0.00175	CcSEcCtD
Methotrexate—Anaemia—Dactinomycin—muscle cancer	0.000104	0.00175	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.000103	0.00174	CcSEcCtD
Methotrexate—Renal failure—Etoposide—muscle cancer	0.000103	0.00172	CcSEcCtD
Methotrexate—Dysarthria—Doxorubicin—muscle cancer	0.000102	0.00172	CcSEcCtD
Methotrexate—Ulcer—Doxorubicin—muscle cancer	0.000102	0.00172	CcSEcCtD
Methotrexate—Alopecia—Vincristine—muscle cancer	0.000102	0.00172	CcSEcCtD
Methotrexate—Stomatitis—Etoposide—muscle cancer	0.000102	0.00171	CcSEcCtD
Methotrexate—Malaise—Dactinomycin—muscle cancer	0.000102	0.00171	CcSEcCtD
Methotrexate—Mental disorder—Vincristine—muscle cancer	0.000101	0.0017	CcSEcCtD
Methotrexate—ABCC2—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000101	0.00943	CbGpPWpGaD
Methotrexate—Leukopenia—Dactinomycin—muscle cancer	0.000101	0.00169	CcSEcCtD
Methotrexate—Inflammation—Doxorubicin—muscle cancer	9.97e-05	0.00167	CcSEcCtD
Methotrexate—ABCB1—embryo—muscle cancer	9.9e-05	0.00247	CbGeAlD
Methotrexate—Hepatobiliary disease—Etoposide—muscle cancer	9.87e-05	0.00166	CcSEcCtD
Methotrexate—Blood uric acid increased—Doxorubicin—muscle cancer	9.85e-05	0.00165	CcSEcCtD
Methotrexate—ABCG2—testis—muscle cancer	9.82e-05	0.00245	CbGeAlD
Methotrexate—Agranulocytosis—Etoposide—muscle cancer	9.74e-05	0.00164	CcSEcCtD
Methotrexate—Back pain—Vincristine—muscle cancer	9.74e-05	0.00164	CcSEcCtD
Methotrexate—Vaginal inflammation—Doxorubicin—muscle cancer	9.68e-05	0.00162	CcSEcCtD
Methotrexate—Pulmonary embolism—Doxorubicin—muscle cancer	9.68e-05	0.00162	CcSEcCtD
Methotrexate—Myalgia—Dactinomycin—muscle cancer	9.59e-05	0.00161	CcSEcCtD
Methotrexate—SLC19A1—Folate Metabolism—TP53—muscle cancer	9.57e-05	0.00895	CbGpPWpGaD
Methotrexate—Discomfort—Dactinomycin—muscle cancer	9.48e-05	0.00159	CcSEcCtD
Methotrexate—Melaena—Doxorubicin—muscle cancer	9.45e-05	0.00159	CcSEcCtD
Methotrexate—Cystitis noninfective—Doxorubicin—muscle cancer	9.45e-05	0.00159	CcSEcCtD
Methotrexate—PGD—Carbohydrate metabolism—ENO2—muscle cancer	9.37e-05	0.00876	CbGpPWpGaD
Methotrexate—Cystitis—Doxorubicin—muscle cancer	9.34e-05	0.00157	CcSEcCtD
Methotrexate—Anaemia—Vincristine—muscle cancer	9.3e-05	0.00156	CcSEcCtD
Methotrexate—Urinary tract disorder—Etoposide—muscle cancer	9.25e-05	0.00155	CcSEcCtD
Methotrexate—Skin exfoliation—Doxorubicin—muscle cancer	9.24e-05	0.00155	CcSEcCtD
Methotrexate—Urethral disorder—Etoposide—muscle cancer	9.18e-05	0.00154	CcSEcCtD
Methotrexate—Infection—Dactinomycin—muscle cancer	9.14e-05	0.00153	CcSEcCtD
Methotrexate—Vaginal infection—Doxorubicin—muscle cancer	9.13e-05	0.00153	CcSEcCtD
Methotrexate—Aplastic anaemia—Doxorubicin—muscle cancer	9.08e-05	0.00153	CcSEcCtD
Methotrexate—Vertigo—Vincristine—muscle cancer	9.04e-05	0.00152	CcSEcCtD
Methotrexate—Leukopenia—Vincristine—muscle cancer	9.01e-05	0.00151	CcSEcCtD
Methotrexate—Thrombocytopenia—Dactinomycin—muscle cancer	9e-05	0.00151	CcSEcCtD
Methotrexate—Erythema multiforme—Etoposide—muscle cancer	8.86e-05	0.00149	CcSEcCtD
Methotrexate—Coma—Doxorubicin—muscle cancer	8.84e-05	0.00148	CcSEcCtD
Methotrexate—Anorexia—Dactinomycin—muscle cancer	8.76e-05	0.00147	CcSEcCtD
Methotrexate—Eye disorder—Etoposide—muscle cancer	8.75e-05	0.00147	CcSEcCtD
Methotrexate—ABCC1—S1P1 pathway—PTGS2—muscle cancer	8.75e-05	0.00818	CbGpPWpGaD
Methotrexate—Bladder pain—Doxorubicin—muscle cancer	8.75e-05	0.00147	CcSEcCtD
Methotrexate—Ecchymosis—Doxorubicin—muscle cancer	8.75e-05	0.00147	CcSEcCtD
Methotrexate—Mouth ulceration—Doxorubicin—muscle cancer	8.75e-05	0.00147	CcSEcCtD
Methotrexate—Neoplasm—Doxorubicin—muscle cancer	8.75e-05	0.00147	CcSEcCtD
Methotrexate—Convulsion—Vincristine—muscle cancer	8.72e-05	0.00146	CcSEcCtD
Methotrexate—Cardiac disorder—Etoposide—muscle cancer	8.69e-05	0.00146	CcSEcCtD
Methotrexate—AOX1—Tryptophan metabolism—MDM2—muscle cancer	8.69e-05	0.00813	CbGpPWpGaD
Methotrexate—Pulmonary oedema—Doxorubicin—muscle cancer	8.61e-05	0.00145	CcSEcCtD
Methotrexate—Myalgia—Vincristine—muscle cancer	8.57e-05	0.00144	CcSEcCtD
Methotrexate—SLC46A1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	8.54e-05	0.00799	CbGpPWpGaD
Methotrexate—ABCC4—Ectoderm Differentiation—DMD—muscle cancer	8.54e-05	0.00798	CbGpPWpGaD
Methotrexate—Angiopathy—Etoposide—muscle cancer	8.5e-05	0.00143	CcSEcCtD
Methotrexate—Immune system disorder—Etoposide—muscle cancer	8.46e-05	0.00142	CcSEcCtD
Methotrexate—Mediastinal disorder—Etoposide—muscle cancer	8.44e-05	0.00142	CcSEcCtD
Methotrexate—Chills—Etoposide—muscle cancer	8.4e-05	0.00141	CcSEcCtD
Methotrexate—Sepsis—Doxorubicin—muscle cancer	8.4e-05	0.00141	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Dactinomycin—muscle cancer	8.38e-05	0.00141	CcSEcCtD
Methotrexate—Alopecia—Etoposide—muscle cancer	8.28e-05	0.00139	CcSEcCtD
Methotrexate—Lymphadenopathy—Doxorubicin—muscle cancer	8.23e-05	0.00138	CcSEcCtD
Methotrexate—Anaphylactic shock—Vincristine—muscle cancer	8.22e-05	0.00138	CcSEcCtD
Methotrexate—Infection—Vincristine—muscle cancer	8.16e-05	0.00137	CcSEcCtD
Methotrexate—Thrombophlebitis—Doxorubicin—muscle cancer	8.11e-05	0.00136	CcSEcCtD
Methotrexate—Diabetes mellitus—Doxorubicin—muscle cancer	8.07e-05	0.00136	CcSEcCtD
Methotrexate—Nervous system disorder—Vincristine—muscle cancer	8.06e-05	0.00135	CcSEcCtD
Methotrexate—Thrombocytopenia—Vincristine—muscle cancer	8.04e-05	0.00135	CcSEcCtD
Methotrexate—Photosensitivity—Doxorubicin—muscle cancer	8e-05	0.00134	CcSEcCtD
Methotrexate—Decreased appetite—Dactinomycin—muscle cancer	7.99e-05	0.00134	CcSEcCtD
Methotrexate—Dysgeusia—Etoposide—muscle cancer	7.99e-05	0.00134	CcSEcCtD
Methotrexate—Hyperhidrosis—Vincristine—muscle cancer	7.94e-05	0.00133	CcSEcCtD
Methotrexate—Fatigue—Dactinomycin—muscle cancer	7.93e-05	0.00133	CcSEcCtD
Methotrexate—Back pain—Etoposide—muscle cancer	7.89e-05	0.00132	CcSEcCtD
Methotrexate—Pain—Dactinomycin—muscle cancer	7.86e-05	0.00132	CcSEcCtD
Methotrexate—Anorexia—Vincristine—muscle cancer	7.83e-05	0.00132	CcSEcCtD
Methotrexate—Hepatic failure—Doxorubicin—muscle cancer	7.81e-05	0.00131	CcSEcCtD
Methotrexate—Hypotension—Vincristine—muscle cancer	7.68e-05	0.00129	CcSEcCtD
Methotrexate—Renal failure acute—Doxorubicin—muscle cancer	7.61e-05	0.00128	CcSEcCtD
Methotrexate—Feeling abnormal—Dactinomycin—muscle cancer	7.58e-05	0.00127	CcSEcCtD
Methotrexate—Ill-defined disorder—Etoposide—muscle cancer	7.57e-05	0.00127	CcSEcCtD
Methotrexate—Anaemia—Etoposide—muscle cancer	7.54e-05	0.00127	CcSEcCtD
Methotrexate—Gastrointestinal pain—Dactinomycin—muscle cancer	7.52e-05	0.00126	CcSEcCtD
Methotrexate—ABCB1—renal system—muscle cancer	7.49e-05	0.00187	CbGeAlD
Methotrexate—Musculoskeletal discomfort—Vincristine—muscle cancer	7.48e-05	0.00126	CcSEcCtD
Methotrexate—Dermatitis exfoliative—Doxorubicin—muscle cancer	7.44e-05	0.00125	CcSEcCtD
Methotrexate—Insomnia—Vincristine—muscle cancer	7.43e-05	0.00125	CcSEcCtD
Methotrexate—Paraesthesia—Vincristine—muscle cancer	7.38e-05	0.00124	CcSEcCtD
Methotrexate—Malaise—Etoposide—muscle cancer	7.35e-05	0.00123	CcSEcCtD
Methotrexate—Vertigo—Etoposide—muscle cancer	7.33e-05	0.00123	CcSEcCtD
Methotrexate—Leukopenia—Etoposide—muscle cancer	7.3e-05	0.00123	CcSEcCtD
Methotrexate—Body temperature increased—Dactinomycin—muscle cancer	7.27e-05	0.00122	CcSEcCtD
Methotrexate—Abdominal pain—Dactinomycin—muscle cancer	7.27e-05	0.00122	CcSEcCtD
Methotrexate—Anaphylactoid reaction—Doxorubicin—muscle cancer	7.26e-05	0.00122	CcSEcCtD
Methotrexate—Lethargy—Doxorubicin—muscle cancer	7.17e-05	0.0012	CcSEcCtD
Methotrexate—Cerebrovascular accident—Doxorubicin—muscle cancer	7.17e-05	0.0012	CcSEcCtD
Methotrexate—Decreased appetite—Vincristine—muscle cancer	7.14e-05	0.0012	CcSEcCtD
Methotrexate—SLC19A1—Metabolism—FH—muscle cancer	7.12e-05	0.00666	CbGpPWpGaD
Methotrexate—Cough—Etoposide—muscle cancer	7.12e-05	0.00119	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Vincristine—muscle cancer	7.09e-05	0.00119	CcSEcCtD
Methotrexate—Fatigue—Vincristine—muscle cancer	7.08e-05	0.00119	CcSEcCtD
Methotrexate—Convulsion—Etoposide—muscle cancer	7.07e-05	0.00119	CcSEcCtD
Methotrexate—Pain—Vincristine—muscle cancer	7.03e-05	0.00118	CcSEcCtD
Methotrexate—Osteoarthritis—Doxorubicin—muscle cancer	7.02e-05	0.00118	CcSEcCtD
Methotrexate—Chest pain—Etoposide—muscle cancer	6.94e-05	0.00117	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	6.89e-05	0.00116	CcSEcCtD
Methotrexate—ABCC1—S1P1 pathway—VEGFA—muscle cancer	6.89e-05	0.00645	CbGpPWpGaD
Methotrexate—Discomfort—Etoposide—muscle cancer	6.86e-05	0.00115	CcSEcCtD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	6.82e-05	0.00638	CbGpPWpGaD
Methotrexate—Hypersensitivity—Dactinomycin—muscle cancer	6.77e-05	0.00114	CcSEcCtD
Methotrexate—Gastrointestinal pain—Vincristine—muscle cancer	6.72e-05	0.00113	CcSEcCtD
Methotrexate—Confusional state—Etoposide—muscle cancer	6.71e-05	0.00113	CcSEcCtD
Methotrexate—MTHFR—Fluoropyrimidine Activity—TP53—muscle cancer	6.66e-05	0.00623	CbGpPWpGaD
Methotrexate—Anaphylactic shock—Etoposide—muscle cancer	6.66e-05	0.00112	CcSEcCtD
Methotrexate—Mood swings—Doxorubicin—muscle cancer	6.65e-05	0.00112	CcSEcCtD
Methotrexate—Infection—Etoposide—muscle cancer	6.61e-05	0.00111	CcSEcCtD
Methotrexate—Ataxia—Doxorubicin—muscle cancer	6.6e-05	0.00111	CcSEcCtD
Methotrexate—Asthenia—Dactinomycin—muscle cancer	6.6e-05	0.00111	CcSEcCtD
Methotrexate—Thrombocytopenia—Etoposide—muscle cancer	6.52e-05	0.00109	CcSEcCtD
Methotrexate—Body temperature increased—Vincristine—muscle cancer	6.49e-05	0.00109	CcSEcCtD
Methotrexate—Abdominal pain—Vincristine—muscle cancer	6.49e-05	0.00109	CcSEcCtD
Methotrexate—Liver function test abnormal—Doxorubicin—muscle cancer	6.48e-05	0.00109	CcSEcCtD
Methotrexate—Skin disorder—Etoposide—muscle cancer	6.46e-05	0.00109	CcSEcCtD
Methotrexate—Hyperhidrosis—Etoposide—muscle cancer	6.43e-05	0.00108	CcSEcCtD
Methotrexate—Breast disorder—Doxorubicin—muscle cancer	6.35e-05	0.00107	CcSEcCtD
Methotrexate—Anorexia—Etoposide—muscle cancer	6.34e-05	0.00107	CcSEcCtD
Methotrexate—SLC46A1—Folate Metabolism—TP53—muscle cancer	6.34e-05	0.00593	CbGpPWpGaD
Methotrexate—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	6.32e-05	0.00106	CcSEcCtD
Methotrexate—Diarrhoea—Dactinomycin—muscle cancer	6.29e-05	0.00106	CcSEcCtD
Methotrexate—ABCC4—Platelet degranulation—IGF2—muscle cancer	6.24e-05	0.00584	CbGpPWpGaD
Methotrexate—Hypotension—Etoposide—muscle cancer	6.22e-05	0.00104	CcSEcCtD
Methotrexate—Asthma—Doxorubicin—muscle cancer	6.07e-05	0.00102	CcSEcCtD
Methotrexate—FPGS—Metabolism—FH—muscle cancer	6.06e-05	0.00566	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—FH—muscle cancer	6.06e-05	0.00566	CbGpPWpGaD
Methotrexate—Hypersensitivity—Vincristine—muscle cancer	6.05e-05	0.00102	CcSEcCtD
Methotrexate—Eosinophilia—Doxorubicin—muscle cancer	6.01e-05	0.00101	CcSEcCtD
Methotrexate—Paraesthesia—Etoposide—muscle cancer	5.98e-05	0.001	CcSEcCtD
Methotrexate—Pancreatitis—Doxorubicin—muscle cancer	5.95e-05	0.000999	CcSEcCtD
Methotrexate—ABCC4—Response to elevated platelet cytosolic Ca2+—IGF2—muscle cancer	5.95e-05	0.00556	CbGpPWpGaD
Methotrexate—Dyspnoea—Etoposide—muscle cancer	5.93e-05	0.000996	CcSEcCtD
Methotrexate—DHFR—Fluoropyrimidine Activity—TP53—muscle cancer	5.92e-05	0.00553	CbGpPWpGaD
Methotrexate—Somnolence—Etoposide—muscle cancer	5.92e-05	0.000994	CcSEcCtD
Methotrexate—Asthenia—Vincristine—muscle cancer	5.89e-05	0.00099	CcSEcCtD
Methotrexate—Vomiting—Dactinomycin—muscle cancer	5.85e-05	0.000982	CcSEcCtD
Methotrexate—Rash—Dactinomycin—muscle cancer	5.8e-05	0.000974	CcSEcCtD
Methotrexate—Decreased appetite—Etoposide—muscle cancer	5.79e-05	0.000971	CcSEcCtD
Methotrexate—Pancytopenia—Doxorubicin—muscle cancer	5.76e-05	0.000968	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Etoposide—muscle cancer	5.75e-05	0.000965	CcSEcCtD
Methotrexate—Fatigue—Etoposide—muscle cancer	5.74e-05	0.000964	CcSEcCtD
Methotrexate—Pain—Etoposide—muscle cancer	5.69e-05	0.000956	CcSEcCtD
Methotrexate—Dysuria—Doxorubicin—muscle cancer	5.68e-05	0.000953	CcSEcCtD
Methotrexate—Neutropenia—Doxorubicin—muscle cancer	5.68e-05	0.000953	CcSEcCtD
Methotrexate—ABCB1—bone marrow—muscle cancer	5.67e-05	0.00141	CbGeAlD
Methotrexate—Upper respiratory tract infection—Doxorubicin—muscle cancer	5.64e-05	0.000947	CcSEcCtD
Methotrexate—DHFR—E2F transcription factor network—CDKN2A—muscle cancer	5.63e-05	0.00527	CbGpPWpGaD
Methotrexate—Diarrhoea—Vincristine—muscle cancer	5.62e-05	0.000944	CcSEcCtD
Methotrexate—Photosensitivity reaction—Doxorubicin—muscle cancer	5.54e-05	0.00093	CcSEcCtD
Methotrexate—Feeling abnormal—Etoposide—muscle cancer	5.48e-05	0.000921	CcSEcCtD
Methotrexate—Nausea—Dactinomycin—muscle cancer	5.46e-05	0.000917	CcSEcCtD
Methotrexate—Pneumonia—Doxorubicin—muscle cancer	5.44e-05	0.000914	CcSEcCtD
Methotrexate—Gastrointestinal pain—Etoposide—muscle cancer	5.44e-05	0.000914	CcSEcCtD
Methotrexate—Dizziness—Vincristine—muscle cancer	5.43e-05	0.000912	CcSEcCtD
Methotrexate—ABCB1—vagina—muscle cancer	5.43e-05	0.00136	CbGeAlD
Methotrexate—Infestation NOS—Doxorubicin—muscle cancer	5.41e-05	0.000909	CcSEcCtD
Methotrexate—Infestation—Doxorubicin—muscle cancer	5.41e-05	0.000909	CcSEcCtD
Methotrexate—Drowsiness—Doxorubicin—muscle cancer	5.41e-05	0.000909	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	5.37e-05	0.000901	CcSEcCtD
Methotrexate—Renal failure—Doxorubicin—muscle cancer	5.32e-05	0.000893	CcSEcCtD
Methotrexate—Urticaria—Etoposide—muscle cancer	5.29e-05	0.000888	CcSEcCtD
Methotrexate—Stomatitis—Doxorubicin—muscle cancer	5.28e-05	0.000886	CcSEcCtD
Methotrexate—Abdominal pain—Etoposide—muscle cancer	5.26e-05	0.000883	CcSEcCtD
Methotrexate—Body temperature increased—Etoposide—muscle cancer	5.26e-05	0.000883	CcSEcCtD
Methotrexate—Conjunctivitis—Doxorubicin—muscle cancer	5.26e-05	0.000883	CcSEcCtD
Methotrexate—Vomiting—Vincristine—muscle cancer	5.22e-05	0.000877	CcSEcCtD
Methotrexate—Sweating—Doxorubicin—muscle cancer	5.19e-05	0.000871	CcSEcCtD
Methotrexate—Rash—Vincristine—muscle cancer	5.18e-05	0.00087	CcSEcCtD
Methotrexate—Dermatitis—Vincristine—muscle cancer	5.18e-05	0.000869	CcSEcCtD
Methotrexate—TYMS—Fluoropyrimidine Activity—TP53—muscle cancer	5.16e-05	0.00483	CbGpPWpGaD
Methotrexate—Haematuria—Doxorubicin—muscle cancer	5.16e-05	0.000867	CcSEcCtD
Methotrexate—MTHFR—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	5.15e-05	0.00482	CbGpPWpGaD
Methotrexate—Headache—Vincristine—muscle cancer	5.15e-05	0.000864	CcSEcCtD
Methotrexate—Hepatobiliary disease—Doxorubicin—muscle cancer	5.12e-05	0.00086	CcSEcCtD
Methotrexate—MTHFR—Selenium Micronutrient Network—PTGS2—muscle cancer	5.11e-05	0.00477	CbGpPWpGaD
Methotrexate—Epistaxis—Doxorubicin—muscle cancer	5.1e-05	0.000857	CcSEcCtD
Methotrexate—Agranulocytosis—Doxorubicin—muscle cancer	5.05e-05	0.000848	CcSEcCtD
Methotrexate—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	5.03e-05	0.00471	CbGpPWpGaD
Methotrexate—ABCB1—head—muscle cancer	5.01e-05	0.00125	CbGeAlD
Methotrexate—SLC22A7—Fluoropyrimidine Activity—TP53—muscle cancer	4.99e-05	0.00466	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	4.98e-05	0.00466	CbGpPWpGaD
Methotrexate—TYMS—E2F transcription factor network—CDKN2A—muscle cancer	4.92e-05	0.0046	CbGpPWpGaD
Methotrexate—Hypersensitivity—Etoposide—muscle cancer	4.9e-05	0.000823	CcSEcCtD
Methotrexate—Haemoglobin—Doxorubicin—muscle cancer	4.88e-05	0.00082	CcSEcCtD
Methotrexate—Nausea—Vincristine—muscle cancer	4.88e-05	0.000819	CcSEcCtD
Methotrexate—Haemorrhage—Doxorubicin—muscle cancer	4.86e-05	0.000816	CcSEcCtD
Methotrexate—Hepatitis—Doxorubicin—muscle cancer	4.86e-05	0.000816	CcSEcCtD
Methotrexate—ABCB1—testis—muscle cancer	4.84e-05	0.00121	CbGeAlD
Methotrexate—Pharyngitis—Doxorubicin—muscle cancer	4.82e-05	0.00081	CcSEcCtD
Methotrexate—Urinary tract disorder—Doxorubicin—muscle cancer	4.8e-05	0.000806	CcSEcCtD
Methotrexate—Asthenia—Etoposide—muscle cancer	4.77e-05	0.000802	CcSEcCtD
Methotrexate—Urethral disorder—Doxorubicin—muscle cancer	4.76e-05	0.0008	CcSEcCtD
Methotrexate—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	4.75e-05	0.00445	CbGpPWpGaD
Methotrexate—DHFR—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	4.75e-05	0.00444	CbGpPWpGaD
Methotrexate—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	4.74e-05	0.00444	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—FH—muscle cancer	4.72e-05	0.00441	CbGpPWpGaD
Methotrexate—Pruritus—Etoposide—muscle cancer	4.71e-05	0.000791	CcSEcCtD
Methotrexate—Visual impairment—Doxorubicin—muscle cancer	4.68e-05	0.000786	CcSEcCtD
Methotrexate—Erythema multiforme—Doxorubicin—muscle cancer	4.59e-05	0.000771	CcSEcCtD
Methotrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	4.58e-05	0.00428	CbGpPWpGaD
Methotrexate—Diarrhoea—Etoposide—muscle cancer	4.55e-05	0.000765	CcSEcCtD
Methotrexate—Eye disorder—Doxorubicin—muscle cancer	4.54e-05	0.000762	CcSEcCtD
Methotrexate—Tinnitus—Doxorubicin—muscle cancer	4.53e-05	0.000761	CcSEcCtD
Methotrexate—Cardiac disorder—Doxorubicin—muscle cancer	4.51e-05	0.000757	CcSEcCtD
Methotrexate—Angiopathy—Doxorubicin—muscle cancer	4.41e-05	0.00074	CcSEcCtD
Methotrexate—Dizziness—Etoposide—muscle cancer	4.4e-05	0.000739	CcSEcCtD
Methotrexate—Immune system disorder—Doxorubicin—muscle cancer	4.39e-05	0.000737	CcSEcCtD
Methotrexate—SLC19A1—Disease—ENO2—muscle cancer	4.38e-05	0.0041	CbGpPWpGaD
Methotrexate—Mediastinal disorder—Doxorubicin—muscle cancer	4.38e-05	0.000735	CcSEcCtD
Methotrexate—Chills—Doxorubicin—muscle cancer	4.36e-05	0.000732	CcSEcCtD
Methotrexate—PGD—Metabolism—FH—muscle cancer	4.31e-05	0.00404	CbGpPWpGaD
Methotrexate—Alopecia—Doxorubicin—muscle cancer	4.29e-05	0.000721	CcSEcCtD
Methotrexate—ABCC3—Fluoropyrimidine Activity—TP53—muscle cancer	4.27e-05	0.004	CbGpPWpGaD
Methotrexate—Mental disorder—Doxorubicin—muscle cancer	4.26e-05	0.000715	CcSEcCtD
Methotrexate—Vomiting—Etoposide—muscle cancer	4.23e-05	0.000711	CcSEcCtD
Methotrexate—Malnutrition—Doxorubicin—muscle cancer	4.23e-05	0.00071	CcSEcCtD
Methotrexate—Erythema—Doxorubicin—muscle cancer	4.23e-05	0.00071	CcSEcCtD
Methotrexate—Rash—Etoposide—muscle cancer	4.2e-05	0.000705	CcSEcCtD
Methotrexate—Dermatitis—Etoposide—muscle cancer	4.19e-05	0.000704	CcSEcCtD
Methotrexate—Headache—Etoposide—muscle cancer	4.17e-05	0.0007	CcSEcCtD
Methotrexate—TYMS—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	4.14e-05	0.00388	CbGpPWpGaD
Methotrexate—Dysgeusia—Doxorubicin—muscle cancer	4.14e-05	0.000696	CcSEcCtD
Methotrexate—Back pain—Doxorubicin—muscle cancer	4.09e-05	0.000687	CcSEcCtD
Methotrexate—ABCC1—Arachidonic acid metabolism—PTGS2—muscle cancer	4.04e-05	0.00377	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—MED12—muscle cancer	4.02e-05	0.00376	CbGpPWpGaD
Methotrexate—ABCC4—Fluoropyrimidine Activity—TP53—muscle cancer	4.02e-05	0.00376	CbGpPWpGaD
Methotrexate—Vision blurred—Doxorubicin—muscle cancer	3.99e-05	0.000669	CcSEcCtD
Methotrexate—SLC19A1—Disease—HMGA1—muscle cancer	3.98e-05	0.00372	CbGpPWpGaD
Methotrexate—Nausea—Etoposide—muscle cancer	3.95e-05	0.000664	CcSEcCtD
Methotrexate—SLC16A1—Hemostasis—ANGPT2—muscle cancer	3.94e-05	0.00368	CbGpPWpGaD
Methotrexate—Ill-defined disorder—Doxorubicin—muscle cancer	3.92e-05	0.000659	CcSEcCtD
Methotrexate—Anaemia—Doxorubicin—muscle cancer	3.91e-05	0.000656	CcSEcCtD
Methotrexate—MTHFR—Folate Metabolism—TP53—muscle cancer	3.82e-05	0.00358	CbGpPWpGaD
Methotrexate—Malaise—Doxorubicin—muscle cancer	3.81e-05	0.00064	CcSEcCtD
Methotrexate—ABCG2—HIF-2-alpha transcription factor network—VEGFA—muscle cancer	3.81e-05	0.00356	CbGpPWpGaD
Methotrexate—Vertigo—Doxorubicin—muscle cancer	3.8e-05	0.000638	CcSEcCtD
Methotrexate—Leukopenia—Doxorubicin—muscle cancer	3.79e-05	0.000636	CcSEcCtD
Methotrexate—FPGS—Disease—ENO2—muscle cancer	3.72e-05	0.00348	CbGpPWpGaD
Methotrexate—Cough—Doxorubicin—muscle cancer	3.69e-05	0.00062	CcSEcCtD
Methotrexate—SLC19A1—Metabolism—ENO2—muscle cancer	3.67e-05	0.00343	CbGpPWpGaD
Methotrexate—Convulsion—Doxorubicin—muscle cancer	3.66e-05	0.000615	CcSEcCtD
Methotrexate—Myalgia—Doxorubicin—muscle cancer	3.6e-05	0.000605	CcSEcCtD
Methotrexate—Arthralgia—Doxorubicin—muscle cancer	3.6e-05	0.000605	CcSEcCtD
Methotrexate—Chest pain—Doxorubicin—muscle cancer	3.6e-05	0.000605	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	3.58e-05	0.0006	CcSEcCtD
Methotrexate—SLC19A1—Disease—FOXO4—muscle cancer	3.57e-05	0.00334	CbGpPWpGaD
Methotrexate—Discomfort—Doxorubicin—muscle cancer	3.56e-05	0.000597	CcSEcCtD
Methotrexate—Confusional state—Doxorubicin—muscle cancer	3.48e-05	0.000584	CcSEcCtD
Methotrexate—Anaphylactic shock—Doxorubicin—muscle cancer	3.45e-05	0.00058	CcSEcCtD
Methotrexate—DHFR—Mitotic G1-G1/S phases—CDKN2A—muscle cancer	3.45e-05	0.00322	CbGpPWpGaD
Methotrexate—Infection—Doxorubicin—muscle cancer	3.43e-05	0.000576	CcSEcCtD
Methotrexate—ATIC—Metabolism—MED12—muscle cancer	3.42e-05	0.0032	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—MED12—muscle cancer	3.42e-05	0.0032	CbGpPWpGaD
Methotrexate—DHFR—Folate Metabolism—TP53—muscle cancer	3.4e-05	0.00318	CbGpPWpGaD
Methotrexate—FPGS—Disease—HMGA1—muscle cancer	3.39e-05	0.00317	CbGpPWpGaD
Methotrexate—Nervous system disorder—Doxorubicin—muscle cancer	3.39e-05	0.000568	CcSEcCtD
Methotrexate—Thrombocytopenia—Doxorubicin—muscle cancer	3.38e-05	0.000568	CcSEcCtD
Methotrexate—Skin disorder—Doxorubicin—muscle cancer	3.35e-05	0.000563	CcSEcCtD
Methotrexate—Hyperhidrosis—Doxorubicin—muscle cancer	3.34e-05	0.00056	CcSEcCtD
Methotrexate—Anorexia—Doxorubicin—muscle cancer	3.29e-05	0.000553	CcSEcCtD
Methotrexate—Hypotension—Doxorubicin—muscle cancer	3.23e-05	0.000542	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Doxorubicin—muscle cancer	3.14e-05	0.000528	CcSEcCtD
Methotrexate—Insomnia—Doxorubicin—muscle cancer	3.12e-05	0.000524	CcSEcCtD
Methotrexate—ATIC—Metabolism—ENO2—muscle cancer	3.12e-05	0.00292	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—ENO2—muscle cancer	3.12e-05	0.00292	CbGpPWpGaD
Methotrexate—Paraesthesia—Doxorubicin—muscle cancer	3.1e-05	0.00052	CcSEcCtD
Methotrexate—Dyspnoea—Doxorubicin—muscle cancer	3.08e-05	0.000517	CcSEcCtD
Methotrexate—Somnolence—Doxorubicin—muscle cancer	3.07e-05	0.000515	CcSEcCtD
Methotrexate—Dyspepsia—Doxorubicin—muscle cancer	3.04e-05	0.00051	CcSEcCtD
Methotrexate—FPGS—Disease—FOXO4—muscle cancer	3.04e-05	0.00284	CbGpPWpGaD
Methotrexate—TYMS—Mitotic G1-G1/S phases—CDKN2A—muscle cancer	3.01e-05	0.00281	CbGpPWpGaD
Methotrexate—Decreased appetite—Doxorubicin—muscle cancer	3e-05	0.000504	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Doxorubicin—muscle cancer	2.98e-05	0.0005	CcSEcCtD
Methotrexate—Fatigue—Doxorubicin—muscle cancer	2.98e-05	0.0005	CcSEcCtD
Methotrexate—Pain—Doxorubicin—muscle cancer	2.95e-05	0.000496	CcSEcCtD
Methotrexate—ABCG2—Fluoropyrimidine Activity—TP53—muscle cancer	2.95e-05	0.00276	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—ANGPT2—muscle cancer	2.94e-05	0.00275	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—ENO2—muscle cancer	2.9e-05	0.00271	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—FH—muscle cancer	2.85e-05	0.00266	CbGpPWpGaD
Methotrexate—Feeling abnormal—Doxorubicin—muscle cancer	2.84e-05	0.000478	CcSEcCtD
Methotrexate—ALB—Platelet degranulation—IGF2—muscle cancer	2.83e-05	0.00264	CbGpPWpGaD
Methotrexate—Gastrointestinal pain—Doxorubicin—muscle cancer	2.82e-05	0.000474	CcSEcCtD
Methotrexate—AOX1—Metabolism—FH—muscle cancer	2.78e-05	0.0026	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—IGF2—muscle cancer	2.77e-05	0.00259	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—BUB1B—muscle cancer	2.77e-05	0.00259	CbGpPWpGaD
Methotrexate—Urticaria—Doxorubicin—muscle cancer	2.74e-05	0.00046	CcSEcCtD
Methotrexate—Abdominal pain—Doxorubicin—muscle cancer	2.73e-05	0.000458	CcSEcCtD
Methotrexate—Body temperature increased—Doxorubicin—muscle cancer	2.73e-05	0.000458	CcSEcCtD
Methotrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	2.72e-05	0.00255	CbGpPWpGaD
Methotrexate—ALB—Response to elevated platelet cytosolic Ca2+—IGF2—muscle cancer	2.69e-05	0.00252	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—MED12—muscle cancer	2.67e-05	0.00249	CbGpPWpGaD
Methotrexate—PGD—Disease—ENO2—muscle cancer	2.65e-05	0.00248	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—FOXO1—muscle cancer	2.64e-05	0.00247	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—HMGA1—muscle cancer	2.64e-05	0.00247	CbGpPWpGaD
Methotrexate—ABCC4—Platelet degranulation—VEGFA—muscle cancer	2.62e-05	0.00245	CbGpPWpGaD
Methotrexate—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	2.59e-05	0.00242	CbGpPWpGaD
Methotrexate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	2.57e-05	0.0024	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.57e-05	0.0024	CbGpPWpGaD
Methotrexate—Hypersensitivity—Doxorubicin—muscle cancer	2.54e-05	0.000427	CcSEcCtD
Methotrexate—DHFR—Metabolism—FH—muscle cancer	2.53e-05	0.00237	CbGpPWpGaD
Methotrexate—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	2.49e-05	0.00233	CbGpPWpGaD
Methotrexate—Asthenia—Doxorubicin—muscle cancer	2.48e-05	0.000416	CcSEcCtD
Methotrexate—DHFR—Cell Cycle—BUB1B—muscle cancer	2.47e-05	0.00231	CbGpPWpGaD
Methotrexate—Pruritus—Doxorubicin—muscle cancer	2.44e-05	0.00041	CcSEcCtD
Methotrexate—PGD—Metabolism—MED12—muscle cancer	2.44e-05	0.00228	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—ENO2—muscle cancer	2.43e-05	0.00227	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—BUB1B—muscle cancer	2.41e-05	0.00226	CbGpPWpGaD
Methotrexate—PGD—Disease—HMGA1—muscle cancer	2.41e-05	0.00226	CbGpPWpGaD
Methotrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	2.38e-05	0.00222	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—FOXO4—muscle cancer	2.37e-05	0.00221	CbGpPWpGaD
Methotrexate—Diarrhoea—Doxorubicin—muscle cancer	2.36e-05	0.000397	CcSEcCtD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.32e-05	0.00217	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—FH—muscle cancer	2.3e-05	0.00215	CbGpPWpGaD
Methotrexate—Dizziness—Doxorubicin—muscle cancer	2.28e-05	0.000383	CcSEcCtD
Methotrexate—FPGS—Disease—FOXO1—muscle cancer	2.24e-05	0.0021	CbGpPWpGaD
Methotrexate—ABCG2—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	2.24e-05	0.0021	CbGpPWpGaD
Methotrexate—PGD—Metabolism—ENO2—muscle cancer	2.22e-05	0.00208	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	2.21e-05	0.00207	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—FH—muscle cancer	2.21e-05	0.00206	CbGpPWpGaD
Methotrexate—Vomiting—Doxorubicin—muscle cancer	2.19e-05	0.000369	CcSEcCtD
Methotrexate—Rash—Doxorubicin—muscle cancer	2.18e-05	0.000365	CcSEcCtD
Methotrexate—Dermatitis—Doxorubicin—muscle cancer	2.17e-05	0.000365	CcSEcCtD
Methotrexate—PGD—Disease—FOXO4—muscle cancer	2.16e-05	0.00202	CbGpPWpGaD
Methotrexate—Headache—Doxorubicin—muscle cancer	2.16e-05	0.000363	CcSEcCtD
Methotrexate—TYMS—Cell Cycle—BUB1B—muscle cancer	2.16e-05	0.00202	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	2.13e-05	0.00199	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	2.1e-05	0.00197	CbGpPWpGaD
Methotrexate—Nausea—Doxorubicin—muscle cancer	2.05e-05	0.000344	CcSEcCtD
Methotrexate—SLCO1B3—Metabolism—FH—muscle cancer	2.02e-05	0.00189	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.02e-05	0.00189	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—KIT—muscle cancer	2.01e-05	0.00188	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—IGF2—muscle cancer	1.91e-05	0.00179	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—FH—muscle cancer	1.83e-05	0.00171	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.82e-05	0.0017	CbGpPWpGaD
Methotrexate—MTHFR—Disease—ENO2—muscle cancer	1.75e-05	0.00164	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—FOXO1—muscle cancer	1.75e-05	0.00163	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.73e-05	0.00161	CbGpPWpGaD
Methotrexate—AOX1—Disease—ENO2—muscle cancer	1.71e-05	0.0016	CbGpPWpGaD
Methotrexate—FPGS—Disease—KIT—muscle cancer	1.71e-05	0.0016	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.68e-05	0.00157	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—MED12—muscle cancer	1.61e-05	0.0015	CbGpPWpGaD
Methotrexate—PGD—Disease—FOXO1—muscle cancer	1.6e-05	0.00149	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HMGA1—muscle cancer	1.59e-05	0.00149	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—FH—muscle cancer	1.59e-05	0.00149	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—MDM2—muscle cancer	1.58e-05	0.00148	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—MED12—muscle cancer	1.57e-05	0.00147	CbGpPWpGaD
Methotrexate—DHFR—Disease—ENO2—muscle cancer	1.56e-05	0.00146	CbGpPWpGaD
Methotrexate—AOX1—Disease—HMGA1—muscle cancer	1.55e-05	0.00145	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	1.54e-05	0.00144	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—PTGS2—muscle cancer	1.53e-05	0.00143	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—ENO2—muscle cancer	1.47e-05	0.00137	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—ENO2—muscle cancer	1.43e-05	0.00134	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—FH—muscle cancer	1.43e-05	0.00134	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—MED12—muscle cancer	1.43e-05	0.00134	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—IGF2—muscle cancer	1.43e-05	0.00134	CbGpPWpGaD
Methotrexate—MTHFR—Disease—FOXO4—muscle cancer	1.43e-05	0.00134	CbGpPWpGaD
Methotrexate—DHFR—Disease—HMGA1—muscle cancer	1.41e-05	0.00132	CbGpPWpGaD
Methotrexate—AOX1—Disease—FOXO4—muscle cancer	1.39e-05	0.0013	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—PTGS2—muscle cancer	1.39e-05	0.0013	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—FH—muscle cancer	1.36e-05	0.00127	CbGpPWpGaD
Methotrexate—FPGS—Disease—MDM2—muscle cancer	1.35e-05	0.00126	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—KIT—muscle cancer	1.33e-05	0.00125	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—ANGPT2—muscle cancer	1.33e-05	0.00124	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—ENO2—muscle cancer	1.3e-05	0.00122	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—MED12—muscle cancer	1.3e-05	0.00122	CbGpPWpGaD
Methotrexate—FPGS—Disease—PTGS2—muscle cancer	1.3e-05	0.00121	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—PTGS2—muscle cancer	1.28e-05	0.0012	CbGpPWpGaD
Methotrexate—DHFR—Disease—FOXO4—muscle cancer	1.27e-05	0.00119	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.27e-05	0.00119	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—CDKN2A—muscle cancer	1.26e-05	0.00118	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—FH—muscle cancer	1.26e-05	0.00118	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—IGF2—muscle cancer	1.25e-05	0.00117	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—MED12—muscle cancer	1.25e-05	0.00117	CbGpPWpGaD
Methotrexate—PGD—Disease—KIT—muscle cancer	1.22e-05	0.00114	CbGpPWpGaD
Methotrexate—TYMS—Circadian rythm related genes—TP53—muscle cancer	1.22e-05	0.00114	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	1.21e-05	0.00113	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—ENO2—muscle cancer	1.19e-05	0.00111	CbGpPWpGaD
Methotrexate—ALB—Platelet degranulation—VEGFA—muscle cancer	1.19e-05	0.00111	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	1.16e-05	0.00109	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—MED12—muscle cancer	1.14e-05	0.00107	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—ENO2—muscle cancer	1.14e-05	0.00106	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—CDKN2A—muscle cancer	1.13e-05	0.00106	CbGpPWpGaD
Methotrexate—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	1.13e-05	0.00106	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—CDKN2A—muscle cancer	1.1e-05	0.00103	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—MDM2—muscle cancer	1.1e-05	0.00102	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—PTGS2—muscle cancer	1.09e-05	0.00102	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—PTGS2—muscle cancer	1.09e-05	0.00102	CbGpPWpGaD
Methotrexate—MTHFR—Disease—FOXO1—muscle cancer	1.05e-05	0.000986	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—VEGFA—muscle cancer	1.05e-05	0.000981	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—MDM2—muscle cancer	1.05e-05	0.000981	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—TP53—muscle cancer	1.04e-05	0.000977	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ENO2—muscle cancer	1.04e-05	0.000976	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—MED12—muscle cancer	1.03e-05	0.000966	CbGpPWpGaD
Methotrexate—AOX1—Disease—FOXO1—muscle cancer	1.03e-05	0.000963	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—PTGS2—muscle cancer	1.01e-05	0.000945	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—MED12—muscle cancer	9.86e-06	0.000922	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—CDKN2A—muscle cancer	9.86e-06	0.000922	CbGpPWpGaD
Methotrexate—PGD—Disease—MDM2—muscle cancer	9.59e-06	0.000897	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—MDM2—muscle cancer	9.56e-06	0.000894	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ENO2—muscle cancer	9.41e-06	0.00088	CbGpPWpGaD
Methotrexate—DHFR—Disease—FOXO1—muscle cancer	9.37e-06	0.000876	CbGpPWpGaD
Methotrexate—PGD—Disease—PTGS2—muscle cancer	9.24e-06	0.000865	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—MED12—muscle cancer	8.99e-06	0.000841	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ENO2—muscle cancer	8.81e-06	0.000824	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PTGS2—muscle cancer	8.46e-06	0.000792	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ENO2—muscle cancer	8.2e-06	0.000767	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	8.16e-06	0.000763	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—MED12—muscle cancer	8.09e-06	0.000757	CbGpPWpGaD
Methotrexate—MTHFR—Disease—KIT—muscle cancer	8.03e-06	0.000751	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—VEGFA—muscle cancer	8.03e-06	0.000751	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HMGA1—muscle cancer	8e-06	0.000749	CbGpPWpGaD
Methotrexate—AOX1—Disease—KIT—muscle cancer	7.85e-06	0.000734	CbGpPWpGaD
Methotrexate—ALB—Metabolism—FH—muscle cancer	7.77e-06	0.000727	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PTGS2—muscle cancer	7.74e-06	0.000724	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—MED12—muscle cancer	7.69e-06	0.000719	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ENO2—muscle cancer	7.37e-06	0.00069	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	7.36e-06	0.000688	CbGpPWpGaD
Methotrexate—ABCC1—Disease—FOXO4—muscle cancer	7.18e-06	0.000671	CbGpPWpGaD
Methotrexate—DHFR—Disease—KIT—muscle cancer	7.14e-06	0.000668	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—MED12—muscle cancer	7.12e-06	0.000666	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ENO2—muscle cancer	7.01e-06	0.000655	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	6.82e-06	0.000637	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—FH—muscle cancer	6.81e-06	0.000637	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	6.57e-06	0.000615	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ENO2—muscle cancer	6.49e-06	0.000607	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IGF2—muscle cancer	6.46e-06	0.000604	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.41e-06	0.000599	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MDM2—muscle cancer	6.33e-06	0.000592	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—TP53—muscle cancer	6.29e-06	0.000588	CbGpPWpGaD
Methotrexate—AOX1—Disease—MDM2—muscle cancer	6.18e-06	0.000578	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTGS2—muscle cancer	6.1e-06	0.00057	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TP53—muscle cancer	6.07e-06	0.000568	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—VEGFA—muscle cancer	5.99e-06	0.00056	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTGS2—muscle cancer	5.96e-06	0.000557	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.77e-06	0.000539	CbGpPWpGaD
Methotrexate—DHFR—Disease—MDM2—muscle cancer	5.62e-06	0.000526	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TP53—muscle cancer	5.49e-06	0.000513	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.48e-06	0.000513	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTGS2—muscle cancer	5.42e-06	0.000507	CbGpPWpGaD
Methotrexate—ABCC1—Disease—FOXO1—muscle cancer	5.3e-06	0.000496	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	5.26e-06	0.000492	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	5.18e-06	0.000484	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTGS2—muscle cancer	5.11e-06	0.000478	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTGS2—muscle cancer	4.99e-06	0.000467	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTGS2—muscle cancer	4.54e-06	0.000424	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—muscle cancer	4.52e-06	0.000423	CbGpPWpGaD
Methotrexate—ALB—Metabolism—MED12—muscle cancer	4.39e-06	0.000411	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTGS2—muscle cancer	4.13e-06	0.000387	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KIT—muscle cancer	4.04e-06	0.000378	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ENO2—muscle cancer	4e-06	0.000375	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTGS2—muscle cancer	3.96e-06	0.00037	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	3.91e-06	0.000366	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—MED12—muscle cancer	3.85e-06	0.00036	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTGS2—muscle cancer	3.63e-06	0.00034	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ENO2—muscle cancer	3.51e-06	0.000328	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTGS2—muscle cancer	3.28e-06	0.000307	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MDM2—muscle cancer	3.18e-06	0.000298	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.13e-06	0.000293	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTGS2—muscle cancer	3.07e-06	0.000287	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTGS2—muscle cancer	2.85e-06	0.000267	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—muscle cancer	2.71e-06	0.000253	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTGS2—muscle cancer	2.57e-06	0.00024	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTGS2—muscle cancer	2.44e-06	0.000228	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS2—muscle cancer	2.26e-06	0.000211	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—muscle cancer	2.05e-06	0.000191	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS2—muscle cancer	1.39e-06	0.00013	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS2—muscle cancer	1.22e-06	0.000114	CbGpPWpGaD
